Login to Your Account

A $6B Opportunity

Ironwood's Linzess Beats PDUFA Date to Approval in IBS

By Marie Powers
Staff Writer

Friday, August 31, 2012

Ironwood Pharmaceuticals Inc. crossed the commercial threshold Thursday morning, gaining FDA approval of irritable bowel syndrome (IBS) drug linaclotide more than a week ahead of the drug's Sept. 9 PDUFA date.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription